Portage Biotech Inc.
PRTG
$6.98
-$1.28-15.50%
| Weiss Ratings | PRTG - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D- | |||
| Reward Grade | E | |||
| Rating Factors | PRTG - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Fair | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Good | |||
| Total Return Index | Very Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | PRTG - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 0.08 | |||
| Price History | PRTG - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | 66.19% | |||
| 30-Day Total Return | 50.11% | |||
| 60-Day Total Return | 40.16% | |||
| 90-Day Total Return | 68.19% | |||
| Year to Date Total Return | 43.03% | |||
| 1-Year Total Return | -33.81% | |||
| 2-Year Total Return | -88.81% | |||
| 3-Year Total Return | -94.57% | |||
| 5-Year Total Return | -96.12% | |||
| 52-Week High % Change | -64.10% | |||
| 52-Week Low % Change | 293.71% | |||
| Price | PRTG - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $23.01 | |||
| 52-Week Low Price | $2.10 | |||
| 52-Week Low Price (Date) | Aug 14, 2024 | |||
| 52-Week High Price (Date) | Sep 18, 2024 | |||
| Valuation | PRTG - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 13.59M | |||
| Enterprise Value | 11.15M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -64.28 | |||
| Earnings Per Share Growth | -50.69% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | -- | |||
| Price/Book (Q) | 6.60 | |||
| Enterprise Value/Revenue (TTM) | -- | |||
| Price | $6.98 | |||
| Enterprise Value/EBITDA (TTM) | -0.95 | |||
| Enterprise Value/EBIT | -0.95 | |||
| Market Cap Category | Nano Cap | |||
| Dividends and Shares | PRTG - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 1.08M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | PRTG - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 203 221 7378 | |||
| Address | -- | |||
| Website | www.portagebiotech.com | |||
| Country | British Virgin Islands | |||
| Year Founded | -- | |||
| Profitability | PRTG - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -- | |||
| Profit Margin | -- | |||
| Management Effectiveness | PRTG - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -15.45% | |||
| Return on Equity | -- | |||
| Income Statement | PRTG - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | -- | |||
| Total Revenue (TTM) | -- | |||
| Revenue Per Share | -- | |||
| Gross Profit (TTM) | -- | |||
| EBITDA (TTM) | -11.72M | |||
| EBIT (TTM) | -11.76M | |||
| Net Income (TTM) | -67.28M | |||
| Net Income Avl. to Common (TTM) | -67.28M | |||
| Total Revenue Growth (Q YOY) | -- | |||
| Earnings Growth (Q YOY) | 73.63% | |||
| EPS Diluted (TTM) | -64.28 | |||
| EPS Diluted Growth (Q YOY) | 78.21% | |||
| Balance Sheet | PRTG - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 1.76M | |||
| Cash Per Share (Q) | $1.64 | |||
| Total Current Assets (Q) | 2.69M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 695.00K | |||
| Current Ratio (Q) | 3.077 | |||
| Book Value Per Share (Q) | $1.25 | |||
| Total Assets (Q) | 2.71M | |||
| Total Current Liabilities (Q) | 873.00K | |||
| Total Debt (Q) | 28.00K | |||
| Total Liabilities (Q) | 2.01M | |||
| Total Common Equity (Q) | 1.40M | |||
| Cash Flow | PRTG - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | 2.81M | |||
| Cash from Financing (TTM) | 5.31M | |||
| Net Change in Cash (TTM) | -1.68M | |||
| Levered Free Cash Flow (TTM) | -6.30M | |||
| Cash from Operations (TTM) | -9.80M | |||
